News & Insights

banner-2.jpg

Nanopharm Announces the Appointment of Mark Clement as Chairman of the Board

NEWPORT, UK, September 2nd, 2016 — Nanopharm, Ltd, a leading provider of tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products (OINDPs), today announced the appointment of Mark Clement as non-executive Chairman of the Board.

Mr. Clement, who has over 25 years of experience in the Life Sciences industry, currently serves as non-executive Chairman or Director of 6 development-stage Life Science companies. He holds an MBA with Distinction from Durham University, where he is now a Visiting Fellow; he is also a Fellow of the Institute of Chartered Accountants and a Chartered Fellow of the Securities and Investment Institute.

Prof. Rob Price, co-Founder and Director of Nanopharm, commented, ‘Mark’s extensive experience in managing Life Science businesses from the perspectives of adviser, founder, investor and Board member, as well as his expertise as a developer of leading service companies including Celsis International, Vectura, and Kuecept, make him an ideal Chairman for Nanopharm.’

‘Mark recognizes Nanopharm’s ability to help the pharmaceutical industry move past the trial-and-error approach to drug development which so often results in failure, and he values the rational scientific strategy we employ to safeguard progression of products into the market,’ said Dr. Jag Shur, Managing Director of Nanopharm. ‘His proven business skills and network will be especially valuable as we are experiencing growing demand for our services.’

‘I’m delighted to be joining such a vibrant company that has achieved a remarkable amount since inception,’ Mr. Clement said. ‘I am convinced that its expertise and know how in the areas of orally inhaled and nasal delivered drugs, together with Nanopharm’s proactive approach to problem solving, can play to a far broader range of customers.’

About Nanopharm
Nanopharm is a leading provider of tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products. The company’s unique processing technologies and formulation development tools enable seamless translation of pre-clinical development through to clinical manufacturing. Nanopharm’s integrated development services in materials characterisation, formulation development and inhaled biopharmaceutics aids successful product development by understanding how material properties and processing conditions influence product functionality. For more information, visit www.nanopharm.co.uk